Inhibition of insulin-induced glucose uptake by atypical protein kinase C isotype-specific interacting protein in 3T3-L1 adipocytes.
Atypical protein kinase C (PKC) isotype-specific interacting protein (ASIP) specifically interacts with the atypical protein kinase C isozymes PKClambda and PKCzeta. ASIP and atypical PKC, as well as their Caenorhabditis elegans counterparts (PAR-3 and PKC-3, respectively), are thought to coordinately participate in intracellular signaling that contributes to the maintenance of cellular polarity and to the formation of junctional complexes. The potential role of ASIP in other cellular functions of atypical PKC was investigated by examining the effect of overexpression of ASIP on insulin-induced glucose uptake, previously shown to be mediated through PKClambda, in 3T3-L1 adipocytes. When overexpressed in these cells, which contain PKClambda but not PKCzeta, ASIP was co-immunoprecipitated with endogenous PKClambda but not with PKCepsilon or with Akt. The subcellular localization of PKClambda was also altered in cells overexpressing ASIP. Overexpression of ASIP inhibited insulin stimulation of both glucose uptake and translocation of the glucose transporter GLUT4 to the plasma membrane, but it did not inhibit glucose uptake induced by either growth hormone or hyperosmolarity both of which promote glucose uptake in a PKClambda-independent manner. Moreover, glucose uptake stimulated by a constitutively active mutant of PKClambda, but not that induced by an active form of Akt, was inhibited by ASIP. Insulin-induced activation of PKClambda, but not that of phosphoinositide 3-kinase or Akt, was also inhibited by overexpression of ASIP. These data suggest that overexpression of ASIP inhibits insulin-induced glucose uptake by specifically interfering with signals transmitted through PKClambda.
Kotani
K
K
Second Department of Internal Medicine, Kobe University School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
Ogawa
W
W
Hashiramoto
M
M
Onishi
T
T
Ohno
S
S
Kasuga
M
M
D016475:3T3 Cells; D000256:Adenoviridae; D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D017173:Caenorhabditis elegans / Q000201:enzymology; D029742:Caenorhabditis elegans Proteins; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005822:Genetic Vectors; D005947:Glucose / Q000493:pharmacokinetics*; D015801:Helminth Proteins / Q000378:metabolism; D007328:Insulin / Q000494:pharmacology*; D007527:Isoenzymes; D051379:Mice; D009419:Nerve Tissue Proteins / Q000494:pharmacology*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors* / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases; D015398:Signal Transduction; D000099293:Protein Kinase C-lambda; D000099221:Protein Kinase C zeta
D029742:Caenorhabditis elegans Proteins; D004791:Enzyme Inhibitors; D005947:Glucose; D015801:Helminth Proteins; D007328:Insulin; D007527:Isoenzymes; D009419:Nerve Tissue Proteins; D011493:Protein Kinase C; D017346:Protein Serine-Threonine Kinases; D000099293:Protein Kinase C-lambda; D000099221:Protein Kinase C zeta; C489275:Hint1 protein, mouse; C097238:PAR-3 protein, C elegans; C115015:PKC-3 protein